These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 1441670)

  • 1. [Therapy of bacterial infections in neutropenic and immunocompromised patients].
    Helbig W; Tauchnitz R
    Z Gesamte Inn Med; 1992 Sep; 47(9):417-21. PubMed ID: 1441670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Empirical antimicrobial therapy in neutropenic patients. Results of a multicenter study by the Infections in Hematology Study Group of the Paul Ehrlich Society].
    Maschmeyer G; Link H; Hiddemann W; Meyer P; Helmerking M; Eisenmann E; Schmitt J; Adam D
    Med Klin (Munich); 1994 Mar; 89(3):114-23. PubMed ID: 8196571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical guidelines for the management of neutropenic patients with unexplained fever in Japan: validation by the Japan Febrile Neutropenia Study Group.
    Tamura K
    Int J Antimicrob Agents; 2005 Dec; 26 Suppl 2():S123-7; discussion S133-40. PubMed ID: 16249072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of fever in neutropenic patients with different risks of complications.
    Klastersky J
    Clin Infect Dis; 2004 Jul; 39 Suppl 1():S32-7. PubMed ID: 15250018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Empirical therapy of infections in neutropenic patients.
    Gaya H
    Br J Haematol; 1998 May; 101 Suppl 1():5-9. PubMed ID: 9607734
    [No Abstract]   [Full Text] [Related]  

  • 6. [Infections in immunosuppressed children].
    Wiger K; Høiby EA; Wathne KO
    Tidsskr Nor Laegeforen; 2005 May; 125(9):1168-72. PubMed ID: 15880153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Antibiotic therapy in leukopenia].
    Böhme A; Shah PM; Stille W; Hoelzer D
    Praxis (Bern 1994); 1998 Sep; 87(36):1120-5. PubMed ID: 9782739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Infections in neutropenic patients].
    Berenguer J
    Enferm Infecc Microbiol Clin; 1995 Feb; 13(2):113-20. PubMed ID: 7711117
    [No Abstract]   [Full Text] [Related]  

  • 9. Effect of granulocyte-colony stimulating factor on empiric therapy with flomoxef sodium and tobramycin in febrile neutropenic patients with hematological malignancies. Kan-etsu Hematological Disease and Infection Study Group.
    Yoshida M; Karasawa M; Naruse T; Fukuda M; Hirashima K; Oh H; Ninomiya H; Abe T; Saito K; Shishido H; Moriyama Y; Shibata A; Motoyoshi K; Nagata N; Miura Y
    Int J Hematol; 1999 Feb; 69(2):81-8. PubMed ID: 10071455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibiotic therapy for gram-negative bacteremia.
    Calandra T; Cometta A
    Infect Dis Clin North Am; 1991 Dec; 5(4):817-34. PubMed ID: 1783770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-risk febrile neutropenia in Auckland 2003-2004: the influence of the microbiology laboratory on patient treatment and the use of pathogen-specific therapy.
    Ritchie S; Palmer S; Ellis-Pegler R
    Intern Med J; 2007 Jan; 37(1):26-31. PubMed ID: 17199841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Empirical antimicrobial therapy in neutropenic patients].
    Maschmeyer G
    Ther Umsch; 1996 Nov; 53(11):854-62. PubMed ID: 8984691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Application of the concepts of evidence-based medicine to the evidence on the treatment of febrile neutropenia].
    Jarque I; Sanz MA
    Enferm Infecc Microbiol Clin; 1999; 17 Suppl 2():95-102. PubMed ID: 10605194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical guidelines for the management of cancer patients with neutropenia and unexplained fever.
    Jun HX; Zhixiang S; Chun W; Reksodiputro AH; Ranuhardy D; Tamura K; Matsumoto T; Lee DG; Purushotaman SV; Lim V; Ahmed A; Hussain Y; Chua M; Ong A; Liu CY; Hsueh PR; Lin SF; Liu YC; Suwangool P; Jootar S; Picazo JJ
    Int J Antimicrob Agents; 2005 Dec; 26 Suppl 2():S128-32; discussion S133-40. PubMed ID: 16253480
    [No Abstract]   [Full Text] [Related]  

  • 15. The changing face of febrile neutropenia-from monotherapy to moulds to mucositis. Why empirical therapy?
    Klastersky J
    J Antimicrob Chemother; 2009 May; 63 Suppl 1():i14-5. PubMed ID: 19372173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The changing face of febrile neutropenia-from monotherapy to moulds to mucositis. Fever and neutropenia: the early years.
    Bodey GP
    J Antimicrob Chemother; 2009 May; 63 Suppl 1():i3-13. PubMed ID: 19372179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infections in immunocompromised patients. II. Established therapy and its limitations.
    Periti P; Mazzei T
    Clin Ther; 1985; 8(1):100-17. PubMed ID: 3854579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of aminoglycosides in neutropenic patients.
    Cometta A; Glauser MP
    Schweiz Med Wochenschr Suppl; 1996; 76():21S-27S. PubMed ID: 8677415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monotherapy versus dual therapy based on risk categorization of febrile neutropenic patients.
    Ohyashiki K
    Clin Infect Dis; 2004 Jul; 39 Suppl 1():S56-8. PubMed ID: 15250023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized trial of cefepime monotherapy or cefepime in combination with amikacin as empirical therapy for febrile neutropenia.
    Tamura K; Imajo K; Akiyama N; Suzuki K; Urabe A; Ohyashiki K; Tanimoto M; Masaoka T;
    Clin Infect Dis; 2004 Jul; 39 Suppl 1():S15-24. PubMed ID: 15250016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.